Understanding CKM Syndrome TAVI Outcomes

Researchers recently evaluated the prevalence and prognostic relevance of cardiovascular-kidney-metabolic (CKM) syndrome in heart valve patients. This multisystem disorder significantly impacts clinical results for individuals receiving heart valves. The study performed a double-center, retrospective analysis of over 5,000 patients. Findings revealed that CKM syndrome TAVI outcomes are closely tied to the number of underlying metabolic and renal conditions present at the time of the procedure.

Furthermore, the investigation showed that nearly 90% of patients undergoing transcatheter aortic valve implantation (TAVI) fulfilled the criteria for CKM syndrome. The researchers used a simplified definition based on the presence of atherosclerotic cardiovascular diseases (ASCVD), chronic kidney disease (CKD), and diabetes mellitus (DM). Consequently, the data demonstrated that procedural success was highest in patients without these conditions. However, success rates dropped progressively as the number of CKM conditions increased.

Prognostic Impact of CKM Syndrome TAVI Outcomes

The study also analyzed 1-year mortality rates to understand how these overlapping conditions affect long-term survival. Specifically, patients with two or three CKM conditions had a significantly higher probability of death within one year compared to those with fewer conditions. For instance, the hazard ratio for mortality in patients with three CKM conditions reached 1.88. Therefore, the presence of multiorgan dysfunction acts as a strong predictor of adverse events following the replacement of the aortic valve.

In addition to mortality, the burden of CKM conditions also influenced other procedural complications. Patients with the highest burden had a higher probability of needing permanent pacemaker implantation. Moreover, the prevalence of this syndrome remained stable over the decade-long study period, highlighting a persistent clinical challenge. Clinicians must identify these multisystem risks early to optimize patient management and improve CKM syndrome TAVI outcomes.

Frequently Asked Questions

What is CKM syndrome in the context of TAVI?

CKM syndrome refers to the pathophysiological interaction between cardiovascular disease, chronic kidney disease, and metabolic disorders like diabetes. In TAVI patients, it represents a high-risk profile that combines valvular heart disease with systemic metabolic and renal dysfunction.

How does CKM syndrome affect 1-year mortality after TAVI?

The risk of death within one year increases significantly with the number of CKM conditions. Patients with all three primary conditions—ASCVD, CKD, and diabetes—face nearly double the mortality risk compared to patients with one or no CKM conditions.

Why is screening for CKM syndrome important before heart surgery?

Screening allows the heart team to identify patients at the highest risk for procedural failure and post-operative complications. By recognizing these multisystem issues, doctors can better tailor perioperative care and long-term follow-up strategies.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Götzinger F et al. Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. Eur J Heart Fail. 2026 Mar 13. doi: undefined. PMID: 41823981.

American Heart Association. Cardiovascular-Kidney-Metabolic Syndrome: Definition, Staging, and Care. AHA Presidential Advisory 2023.

Ndumele CE et al. A Presidential Advisory From the American Heart Association. Circulation. 2023;148:1606–1635.